The mcPCR platform enables copying of DNA methylation patterns during amplification, addressing a key limitation in current PCR methods for disease detection.
Syndex Bio unveiled its mcPCR (methyl-copying PCR) platform at the Advances in Genome Biology and Technology conference in Orlando, Florida. The technology enables high-fidelity copying of DNA methylation patterns alongside genetic code during DNA amplification, addressing a fundamental limitation of standard PCR methods.
The Cambridge, UK-based biotechnology company also closed an oversubscribed $15.5 million seed financing round led by ARCH Venture Partners, with participation from +ND Capital, OMX Ventures, and Meltwind.
Traditional PCR cannot amplify DNA methylation patterns that are critical for detecting many diseases, including cancer. The mcPCR platform aims to enable simpler, faster, and more sensitive analysis of methylated DNA for clinical sample testing, particularly in non-invasive and small-sample biopsies for early disease detection and monitoring.
“Syndex Bio’s mcPCR platform makes amplifying DNA methylation possible for the first time. This powerful method will redefine the sensitivity and accuracy that is achievable in DNA methylation analysis, opening new possibilities for early detection and disease monitoring,” says Geoff Smith, PhD, founder and chief executive officer of Syndex Bio, in a release.
Funding to Support Platform Expansion
The seed funding will support expansion of the mcPCR platform, development of clinical workflows and applications, and build-out of the company’s research and development operations in Cambridge.
Gautam Kollu, former chief commercial officer of Grail, joined the newly formed board of directors alongside Patrick Weiss (chairman), Geoff Smith, Sean Kendall, and Eric Moessinger.
“The mcPCR platform removes the technical barriers that have long limited epigenetics, finally allowing us to tap into the highest-value segments of the molecular diagnostics market,” says Kollu, board member at Syndex Bio, in a release. “This capability is essential for expanding precise clinical testing across diverse disease areas, where sensitivity has historically been the bottleneck.”
Clinical Applications in Development
The technology targets applications in cancer screening, chronic disease detection, and basic research where DNA methylation analysis is critical. By enabling PCR amplification of methylation patterns, the platform could improve sensitivity in detecting diseases from small sample volumes.
“This milestone is testament to Syndex Bio’s talented team and their extraordinary efforts in launching this foundational technology,” says Sean Kendall, board member at Syndex Bio and partner at ARCH Venture Partners, in a release. “We believe mcPCR holds the potential to elevate the accuracy and speed of cancer screening and diagnosis.”
Photo caption: mcPCR
Photo credit: Syndex Bio
